Kari Alitalo

TL;DR: It is shown that combined use of antibodies blocking ligand binding and receptor dimerization improves VEGFR inhibition and results in stronger inhibition of endothelial sprouting and vascular network formation in vivo, suggesting that receptor Dimerization inhibitors could be used to enhance antiangiogenic activity of antibodiesblocking ligandbinding in tumor therapy.

TL;DR: The data indicate that VEGF‐B could be used to increase the coronary vasculature and to reprogram myocardial metabolism to improve cardiac function in ischemic heart disease.

TL;DR: Cell-cell communication during vascular development and tumour angiogenesis seems to involve at least five endothelial cell-specific tyrosine kinase receptors belonging to two distinct subclasses: two receptors of the Tie family, and three vascular endothelialcell growth factor receptors.

TL;DR: Together, these experiments show that in the mouse VAP-1 is the only source of serum SSAO, that under physiological conditions vascular endothelial cells can be a major source of circulating V AP-1 protein and SsaO, and that serum VAP -1 can originate from both endothelium cells and adipocytes during experimental diabetes.

TL;DR: It is shown that the prototypic angiogenic factor VEGF is secreted by the floor plate and is a chemoattractant for commissural axons in vitro and in vivo and identifies VEGf and Flk1 as a novel ligand/receptor pair controlling commissur axon guidance.